OX40 treatment has been reported to increase expression of ICOS on both CD4 and CD8 T-cells, and modulating this pathway can impact the therapeutic response to anti-OX40 antibodies in mouse models of cancer (Metzger et al., 2016). Here, CD4 is linked to cancer.